Skip to content

For research use only. Not for human or animal consumption. Ships to US addresses only.

Research News

Nov 20, 2026 · 2 min readIncretin AnalogsClinical Trials

Semaglutide and Muscle Function in Obese Mice

In obese mice, semaglutide produced more weight loss than energy-matched caloric restriction without impairing muscle function.

A preclinical study in the Journal of Cachexia, Sarcopenia and Muscle (Minderis et al., 2026) compared semaglutide with energy-matched caloric restriction in obese mice and found that semaglutide did not impair skeletal muscle function and was associated with better treadmill endurance. The work is in mice only, and its authors do not extend the findings to people.

What happened

Semaglutide, a GLP-1 receptor agonist, lowers body weight mainly by suppressing appetite, but part of the weight lost is lean mass. The researchers, based at the Lithuanian Sports University, asked how this compares with conventional caloric restriction in terms of muscle mass, muscle function and exercise capacity.

Study design

The study used 8-month-old male C57BL/6J mice made obese with a high-fat diet. For 28 days, one group received semaglutide injections and a pair-fed group underwent energy-matched caloric restriction with sham PBS injections (n = 14 per group). A third group of obese mice (n = 12) continued unrestricted high-fat feeding as controls. During the final week, exercise capacity was tested on a progressive treadmill with oxygen consumption and lactate measurements. Afterwards the soleus (slow-twitch) and extensor digitorum longus (fast-twitch) muscles were weighed and tested ex vivo for mechanical and contractile properties.

Results

  • Body mass: despite similar energy intake, semaglutide mice lost more body mass than caloric-restriction mice (20.9 ± 4.9% vs 14.8 ± 5.8%, p < 0.01).
  • Muscle mass: soleus mass was lower in both treated groups than in controls (controls 10.0 ± 0.7 mg; semaglutide 9.1 ± 0.8 mg, p < 0.01; caloric restriction 9.4 ± 0.7 mg, p < 0.05). Extensor digitorum longus mass did not differ significantly.
  • Endurance: relative peak oxygen consumption (VO2 peak) was higher with semaglutide (43.4 ± 3.0 mL/min/kg^0.75) than with caloric restriction (40.8 ± 2.6, p < 0.05) or control (38.6 ± 2.69, p < 0.001). Running distance and maximal speed also favored semaglutide, but the authors attribute these largely to lower body mass.
  • Muscle force: force normalized to muscle mass and to cross-sectional area did not differ between groups in either muscle, and contraction and relaxation kinetics were similar.

The authors conclude that semaglutide induced greater weight loss but similar muscle loss compared with energy-matched caloric restriction, while improving aerobic endurance without compromising muscle function.

Limitations

These are male mice from a single strain on a high-fat diet, studied over 28 days, with modest group sizes. The soleus mass reduction in both treated groups shows that some muscle loss accompanied weight loss. Muscle and exercise results in mice do not necessarily carry over to humans, and the study did not measure human outcomes. Funding was from the Research Council of Lithuania.

Context

Concern about lean mass loss during incretin-based weight loss is an active research question in obesity medicine. A controlled animal comparison with caloric restriction helps separate drug effects from the effects of weight loss itself, but human trials with body-composition and functional endpoints are needed to answer the clinical question.

Sources

Sources

  1. Minderis et al., J Cachexia Sarcopenia Muscle 2026 (PMID 43041190)
  2. DOI 10.1002/jcsm.70427

For research use only. Not for human or animal consumption. This article summarizes published research for scientific information only. It is not medical advice and makes no claim about any use in people or animals. These products have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). They are not intended to diagnose, treat or prevent any disease.